SOPHiA GENETICS SA
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Aug 4, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Platform Analysis Volume
Platform Analysis Volume
The following table shows platform analysis volume for the three and six months ended June 30, 2026 and 2025:
| Three months ended June 30, | Six months ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| SOPHiA DDM Platform analysis volume* | 115,432 | 94,562 | 223,008 | 187,570 |
*The figures in the table above have been adjusted to exclude analyses conducted during the period but for which chargebacks were issued or other adjustments were made to customers after the period. We do not believe that such adjustments are material to the periods presented.
Platform analysis volume represents a key business metric that reflects our overall business performance, as we generate revenue on a pay-per-analysis basis. Platform analysis volume measures the number of analyses that generated revenue to us and were conducted by our Core Genomics Customers. Analysis volume is a direct function of the number of active customers and usage rates across our customer base during a specified time period. While our platform analysis volume is a major driver of our revenue growth, other factors, including application and product pricing, access model used, and customer size mix, also affect our revenue. Because of that, our revenue may increase in periods in which our analysis volume decreases and vice versa.
Analysis volume increased to 115,432 from 94,562 and 223,008 from 187,570 for the three and six months ended June 30, 2026, representing year-over-year growth of 22% and 19% for the three and six months ended June 30, 2026, respectively. This increase is primarily attributable to increased usage from our existing customers as well as new customers onboarded onto our platform, primarily related to strong volume growth in EMEA and NORAM. Hematological Oncology and Hereditary Cancer applications were the primary drivers of the increased volume. We typically increase prices annually or as necessary throughout the year as contracts renew. While platform analysis volume is a primary driver of our overall revenue, there are other important factors that also contribute to our revenue performance, including access model mix, Alamut license sales, biopharma service revenue and workflow equipment and services revenue. These factors also contributed to year-over-year growth in our overall revenue in 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.